Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Candel Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −1 vs. Q1 2023
- Shares held
- 5.37M
- −108.2K (−2.0%) vs. Q1 2023
- Total value
- $6.77M
- −$671.1K (−9.0%) vs. Q1 2023
- New holders
- 2
- 3 more added
- Sold out
- 3
- 5 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CADL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 137 | $518.9M |
| Q1 2026 | 114 | $212.9M |
| Q4 2025 | 84 | $133.5M |
| Q3 2025 | 81 | $115.6M |
| Q2 2025 | 78 | $116.6M |
| Q1 2025 | 82 | $119.7M |
| Q4 2024 | 71 | $155.7M |
| Q3 2024 | 52 | $46.4M |
| Q2 2024 | 45 | $37.0M |
| Q1 2024 | 20 | $5.97M |
| Q4 2023 | 22 | $5.92M |
| Q3 2023 | 20 | $4.86M |
| Q2 2023 | 20 | $6.77M |
| Q1 2023 | 21 | $7.44M |
| Q4 2022 | 21 | $9.70M |
| Q3 2022 | 25 | $19.1M |
| Q2 2022 | 23 | $20.6M |
| Q1 2022 | 23 | $34.0M |
| Q4 2021 | 20 | $54.4M |
| Q3 2021 | 12 | $52.9M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Candel Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Northpond Ventures, LLC | 1,935,215 | $2.44M | 4.05% | 00.0% | Unchanged |
| Franklin Resources Inc | 1,125,000 | $1.42M | 0.00% | 00.0% | Unchanged |
| Sands Capital Ventures, LLC | 811,737 | $1.02M | 0.30% | 00.0% | Unchanged |
| FMR LLC | 452,557 | $570.2K | 0.00% | −160,600−26.2% | Reduced |
| Vanguard Group Inc | 405,755 | $511.3K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 132,595 | $167.1K | 0.00% | −105−0.1% | Reduced |
| Geode Capital Management, LLC | 131,203 | $165.3K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 118,612 | $149.5K | 0.00% | +118,612 | New |
| Baystate Wealth Management LLC | 100,540 | $126.7K | 0.01% | −5,314−5.0% | Reduced |
| BlackRock Inc. | 51,823 | $65.3K | 0.00% | +5,279+11.3% | Added |
| State Street Corp | 27,600 | $34.8K | 0.00% | 00.0% | Unchanged |
| Resources Investment Advisors, LLC. | 25,428 | $32.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 19,617 | $24.7K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 12,800 | $16.0K | 0.00% | −8,200−39.0% | Reduced |
| Empirical Asset Management, LLC | 11,000 | $13.9K | 0.01% | −1,000−8.3% | Reduced |
| Tower Research Capital LLC (TRC) | 8,262 | $10.4K | 0.00% | +1,686+25.6% | Added |
| JPMorgan Chase & Co | 186 | $234 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 104 | $131 | 0.00% | +4+4.0% | Added |
| UBS Group AG | 10 | $13 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 163 | $0 | 0.00% | +163 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −47,174−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −11,416−100.0% | Sold out |
| Quent Capital, LLC | 0 | $0 | 0.00% | −182−100.0% | Sold out |